Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
54 results
  • Thyroid Cancer, Sarcoma, Pancreatic Cancer, Ovarian Cancer, Lung Cancer, Breast Cancer, Kidney Cancer, Head and Neck Cancer, Liver Cancer

23-301          Phase I

A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors

  • Colorectal Cancer, Lung Cancer

20-177          Phase I

A First-in-Human, Phase 1a/1b, Open-Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients with Advanced or Refractory Tumors

  • Melanoma, Lymphoma, Lung Cancer, Head and Neck Cancer

21-258          Phase II

A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab

  • Melanoma, Bladder Cancer, Head and Neck Cancer, Lung Cancer

18-418          Phase III

A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.

  • Lung Cancer

22-705          Phase I

A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects with Non-Small Cell Lung Cancer – KisMET-01

  • Lung Cancer

20-601          Phase I

A Phase 1 Open-Label Study of Patritumab Deruxtecan in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)

  • Lung Cancer

23-036          Phase I

A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of PT217 in Patients with Advanced Refractory Cancers Expressing DLL3

  • Lung Cancer

23-075          Phase I

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

  • Lung Cancer, Ovarian Cancer, Breast Cancer, Esophageal Cancer, Cervical Cancer, Head and Neck Cancer

22-281          Phase I

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and in Combination With Chemotherapy in Patients With Advanced or Metastatic Solid Tumors

  • Head and Neck Cancer, Thyroid Cancer, Lung Cancer

22-124          Phase I

A Phase 1 Study of Oral LOXO-260 in Patients with RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation Refractory to Selective RET Inhibitors

Showing 1 - 10 of 54 results